Natera, Inc. (NTRA) Analysts See $-0.43 EPS; 4 Analysts Covering Old National Bancorp (ONB)

February 13, 2018 - By Marguerite Chambers

Among 10 analysts covering Old National Bancorp (NASDAQ:ONB), 4 have Buy rating, 0 Sell and 6 Hold. Therefore 40% are positive. Old National Bancorp had 26 analyst reports since August 4, 2015 according to SRatingsIntel. The stock has “Hold” rating by RBC Capital Markets on Wednesday, October 4. The rating was initiated by Stephens on Tuesday, August 4 with “Overweight”. As per Friday, October 13, the company rating was maintained by Keefe Bruyette & Woods. Jefferies maintained the shares of ONB in report on Friday, August 11 with “Hold” rating. On Tuesday, August 2 the stock rating was maintained by Wood with “Market Perform”. The company was initiated on Monday, July 11 by Piper Jaffray. Keefe Bruyette & Woods maintained Old National Bancorp (NASDAQ:ONB) on Tuesday, January 23 with “Hold” rating. The firm has “Buy” rating given on Friday, February 9 by Hilliard Lyons. The stock of Old National Bancorp (NASDAQ:ONB) earned “Hold” rating by RBC Capital Markets on Tuesday, October 24. The company was maintained on Tuesday, August 8 by RBC Capital Markets. See Old National Bancorp (NASDAQ:ONB) latest ratings:

09/02/2018 Broker: Hilliard Lyons Old Rating: Neutral New Rating: Buy Upgrade
23/01/2018 Broker: Keefe Bruyette & Woods Rating: Hold New Target: $19.0 Maintain
21/12/2017 Broker: Keefe Bruyette & Woods Rating: Hold New Target: $20.0 Maintain
24/10/2017 Broker: RBC Capital Markets Rating: Hold New Target: $19.0 Maintain
13/10/2017 Broker: Keefe Bruyette & Woods Rating: Hold New Target: $18.0 Maintain
06/10/2017 Broker: Piper Jaffray Rating: Hold New Target: $19.0 Initiate
04/10/2017 Broker: RBC Capital Markets Rating: Hold New Target: $18.0 Maintain
04/10/2017 Broker: Boenning & Scattergood Rating: Buy New Target: $20.5
19/09/2017 Broker: Raymond James Old Rating: Market Perform New Rating: Outperform Upgrade
15/09/2017 Broker: Jefferies Rating: Hold New Target: $18.0 Maintain

Analysts expect Natera, Inc. (NASDAQ:NTRA) to report $-0.43 EPS on March, 6.They anticipate $0.29 EPS change or 40.28% from last quarter’s $-0.72 EPS. After having $-0.51 EPS previously, Natera, Inc.’s analysts see -15.69% EPS growth. The stock decreased 0.99% or $0.09 during the last trading session, reaching $9.04. About 3,467 shares traded. Natera, Inc. (NASDAQ:NTRA) has declined 8.45% since February 13, 2017 and is downtrending. It has underperformed by 25.15% the S&P500.

Among 7 analysts covering Natera Inc (NASDAQ:NTRA), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Natera Inc had 22 analyst reports since July 27, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Tuesday, April 19 by Benchmark. The company was maintained on Monday, October 23 by Canaccord Genuity. Piper Jaffray initiated the shares of NTRA in report on Monday, July 27 with “Overweight” rating. The company was initiated on Monday, July 27 by Morgan Stanley. Canaccord Genuity maintained the stock with “Buy” rating in Tuesday, November 14 report. The rating was maintained by Cowen & Co with “Buy” on Wednesday, December 20. The rating was maintained by Morgan Stanley on Monday, August 7 with “Overweight”. On Monday, October 23 the stock rating was maintained by Robert W. Baird with “Buy”. The stock of Natera, Inc. (NASDAQ:NTRA) has “Outperform” rating given on Monday, July 27 by Cowen & Co. Morgan Stanley maintained the stock with “Overweight” rating in Friday, October 6 report.

Natera, Inc., a diagnostics company, provides preconception and prenatal genetic testing services. The company has market cap of $486.07 million. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus typically with a blood draw from the mother; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. It currently has negative earnings. The firm also provides products of conception testing under the Anora brand to analyze fetal chromosomes to understand the cause of miscarriage; non-invasive paternity testing products to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father.

Old National Bancorp operates as the holding firm for Old National Bank that provides various financial services to individual and commercial clients in the United States. The company has market cap of $2.62 billion. The firm offers deposit accounts, including noninterest-bearing demand, negotiable order of withdrawal, savings and money market, and time deposits; and loans, such as home equity lines of credit, residential real estate loans, consumer loans, commercial loans, commercial real estate loans, letters of credit, and lease financing. It has a 24.93 P/E ratio. It also provides debit and ATM cards, telephone access, and online banking, as well as other electronic and mobile banking services; and cash management, private banking, brokerage, trust, and investment advisory services.

It closed at $17.2 lastly. It is down 28.89% since February 13, 2017 and is uptrending. It has outperformed by 12.19% the S&P500.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>